Study | Participants | Size | Female % | Median age (range)*mean | Serological test | HSV-2 test results | Psychosocial assessment | Follow-up | Summary results |
Qualitative cohort | |||||||||
Melville26 (USA, 2003) |
| 24 | 58 | 35 (19–55) | HSV western blot | Positive, per inclusion criteria 24/24 | 1 h semi-structured interview | Post results (<1 month to 1 year post-diagnosis) | Subjects reported surprise, fear of transmission/disclosure, feeling undesirable and ongoing acceptance over time. Knowledge and social support were moderators of response. |
Prospective cohorts | |||||||||
Mark25 (USA, 2008) |
| 100 | 64 | 24.5* (18–39) | HerpeSelect and western blot | Eight (9%) tested positive by ELISA, three confirmed by western blot |
| 3 months | Significant increase in GHQ-30 for HSV-2 positives compared with negatives at 2 months (13 points↑ vs. 3 points ↓, p<0.05). Slight ↑ on CES-D for positives, but not significant. Four out of eight positives asked for additional meeting with staff. |
Meyer27 (USA, 2005) |
| 248 | 15 | 40 (22–66) | HSV western blot | 172 (69.4%) positive, 116 without previous history of genital HSV |
| 2 weeks, 3 months, 6 months | No significant changes on any measure over time for positive subjects, no significant difference when comparing positive and negative subjects or subjects with previous HSV-2 history. |
Miyai28 (USA, 2004) |
| 196 | 17 |
| HerpeSelect 2 | 41 (21%) tested positive |
| 1 week, 3 months | No change in MHI-5 at 1 week (0.33, p=0.44) or 3 months (0.31, p=0.6) in HSV-2-positive participants relative to baseline, no significant difference between positive and negative groups. Decline in sexual attitude at 1 week for positive subjects compared with negative subjects, resolved by 3 months. |
Narouz29 (UK, 2003) |
| 223 | 52 | 28 (16–66) | Gull/Meridian gG EIA | 43 (20%) tested positive for HSV-2, 14 had a previous history of genital herpes | Subjects asked if they regretted having testing done when given results | 1 week | Three patients regretted being tested. Four out of 43 people who were positive contacted department for more counselling. |
Richards30 (USA, 2007) | Urban HMO enrollees recruited via mail and phone | 201 | 60 | 46 (19–67) | HSV western blot | 26% (87 of 344) tested positive, 44 without previous diagnosis of HSV-2, 87 positives and 114 negatives were enrolled in the follow-up study |
| 2 weeks, 3 months, 6 months | 6% ↑ on mood disturbance for newly diagnosed subjects relative to baseline (p=0.003), no significant difference when comparing between groups except within HSV-specific mood disturbance. At 2 weeks, newly diagnosed coped by wishing situation would disappear (0.038 points higher, p=0.014) relative to previously diagnosed and other time points (0.37, p<0.001). |
Rosenthal31 (USA, 2006) |
| 93 | 87 | 22.7* (criteria: 14–30 years) | HSV-2 antibody test | 18% (149 of 820) tested positive, 33 positives and 60 negatives were enrolled in the follow-up study |
| 3 months | No significant difference between positive and negative subjects on depression, anxiety, paranoia, hostility, interpersonal sensitivity, STD stigma, relationship quality, or quality of sex. No effect for time. |
Smith32 (AU, 2000) |
| 180 | 46 |
| HSV-2 enzyme immunoassay and HSV-1 western blot | 21 (11.7%) tested positive |
| 3 months, 6 months | No change in GHQ-12 or other scales for HSV-2-positive or negative participants over time. |
Wilkinson33 (UK, 2000) letter to the editor |
| 90 | 50 | Not specified | POCKit HSV-2 | 51 (57%) tested positive, 25 without previous HSV-2 diagnosis | Hospital anxiety and depression questionnaire (HAD) | 3 months, 6 months | No significant difference in the number of cases of anxiety or depression in those who tested positive with or without a previous history of HSV-2. |
↵* Mean age.
EIA, enzyme immunoassay; ELISA, enzyme-linked immunosorbent assay; HMO, health maintenance organisation; HSV, herpes simplex virus; STD, sexually transmitted disease.